Insider Selling Continues at Arcutis Biotherapeutics
The latest Rule 4 filing from Welgus Howard G. on May 1, 2026 shows a sale of 7,144 shares of Arcutis Common Stock at a weighted average price of $22.99, leaving Howard with 32,600 shares. This sale is part of a 10‑b‑5‑1 trading plan that began in March 2025 and will expire in May 2026. The transaction is consistent with a routine, plan‑driven exit rather than a reaction to a specific catalyst, but the cumulative volume of Howard’s sales over the past 18 months—approximately 77,000 shares—raises questions about long‑term confidence in the company’s prospects.
What Does This Mean for Investors? Arcutis’s share price has risen nearly 71 % year‑to‑year, yet the firm’s price‑to‑earnings ratio is a dismal –183.85, reflecting a negative earnings base that investors must navigate. The steady stream of insider sales, coupled with a high market cap of $2.92 billion and a lack of recent corporate announcements, suggests that insiders may be reallocating capital toward other opportunities rather than betting on the company’s immediate upside. For long‑term holders, the pattern could indicate that the current valuation is already priced in most of the upside, or that the leadership is seeking liquidity to fund other initiatives.
Howard’s Trading Profile Howard’s insider activity over the last year has been heavily skewed toward selling, with only a handful of small purchases. Since the inception of the 10‑b‑5‑1 plan, he has sold roughly 70 % of the shares he originally held, averaging about $25 per share—well above the current market price. The most recent sale on May 1, 2026 was at $22.99, slightly below the market close of $23.49, indicating that the plan’s schedule is the primary driver. Historically, Howard’s sales have clustered in the $20–$30 range, suggesting confidence in the company’s valuation at those levels but a willingness to divest as the price rises.
Looking Ahead Arcutis’s clinical pipeline remains its core driver, yet the company has yet to announce a breakthrough product launch or a significant partnership. The continued insider selling may dampen enthusiasm among cautious investors, but the firm’s robust cash position and the absence of any negative earnings surprises keep it in the growth category for many. For those eyeing a mid‑term investment horizon, the current price may represent a “buy the dip” opportunity before the next insider sale event—especially if the company can convert its clinical momentum into a positive earnings trajectory.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-05-01 | Welgus Howard G. () | Sell | 7,144.00 | 22.99 | Common Stock |
